Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA, a Randomized Controlled Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever minor stroke or TIA compared to 200mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• the investigators included both genders with eligible ages ranging between 18-75 years, with the first-ever presentation with minor ischemic stroke or TIA who received antiplatelet treatment within the first 24 hours of the onset of ischemic stroke. Patients are not eligible for rt-PA treatment
Locations
Other Locations
Egypt
Kafr Elsheikh University Hospital
RECRUITING
Kafr Ash Shaykh
Contact Information
Primary
mohamed G. Zeinhom, MD
mohamed_gomaa@med.kfs.edu.eg
2001009606828
Backup
sherihan R. ahmed, MD
sherihan_rezq@med.kfs.edu.eg
2001113432342
Time Frame
Start Date: 2022-02-09
Estimated Completion Date: 2024-10-01
Participants
Target number of participants: 900
Treatments
Active_comparator: Ticagrelor and aspirin arm
The ticagrelor arm will receive (a 180 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Active_comparator: cilostazol and aspirin arm
The cilostazol arm will receive (a 200 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Related Therapeutic Areas
Sponsors
Leads: Kafrelsheikh University